Summary
Global Markets Direct’s, ‘Chondrosarcoma - Pipeline Review, H1 2016’, provides an overview of the Chondrosarcoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma
- The report reviews pipeline therapeutics for Chondrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chondrosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Chondrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chondrosarcoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Agios Pharmaceuticals, Inc.
Celgene Corporation
CytRx Corporation
EpiZyme, Inc.
Horizon Pharma Plc
Karyopharm Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chondrosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Chondrosarcoma - Overview 7
Pipeline Products for Chondrosarcoma - Comparative Analysis 8
Chondrosarcoma - Therapeutics under Development by Companies 9
Chondrosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Chondrosarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Chondrosarcoma - Products under Development by Companies 12
Chondrosarcoma - Products under Investigation by Universities/Institutes 13
Chondrosarcoma - Companies Involved in Therapeutics Development 14
Agios Pharmaceuticals, Inc. 14
Celgene Corporation 15
CytRx Corporation 16
EpiZyme, Inc. 17
Horizon Pharma Plc 18
Karyopharm Therapeutics, Inc. 19
Merck & Co., Inc. 20
Novartis AG 21
Chondrosarcoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
AG-120 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
aldoxorubicin hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CC-90007 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
interferon gamma-1b - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pazopanib hydrochloride - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pembrolizumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
selinexor - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
tazemetostat - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Chondrosarcoma - Recent Pipeline Updates 70
Chondrosarcoma - Dormant Projects 130
Chondrosarcoma - Discontinued Products 131
Chondrosarcoma - Product Development Milestones 132
Featured News & Press Releases 132
May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 132
Appendix 134
Methodology 134
Coverage 134
Secondary Research 134
Primary Research 134
Expert Panel Validation 134
Contact Us 134
Disclaimer 135
List of Tables
Number of Products under Development for Chondrosarcoma, H1 2016 7
Number of Products under Development for Chondrosarcoma - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Products under Investigation by Universities/Institutes, H1 2016 13
Chondrosarcoma - Pipeline by Agios Pharmaceuticals, Inc., H1 2016 14
Chondrosarcoma - Pipeline by Celgene Corporation, H1 2016 15
Chondrosarcoma - Pipeline by CytRx Corporation, H1 2016 16
Chondrosarcoma - Pipeline by EpiZyme, Inc., H1 2016 17
Chondrosarcoma - Pipeline by Horizon Pharma Plc, H1 2016 18
Chondrosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 19
Chondrosarcoma - Pipeline by Merck & Co., Inc., H1 2016 20
Chondrosarcoma - Pipeline by Novartis AG, H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Chondrosarcoma Therapeutics - Recent Pipeline Updates, H1 2016 70
Chondrosarcoma - Dormant Projects, H1 2016 130
Chondrosarcoma - Discontinued Products, H1 2016 131
List of Figures
Number of Products under Development for Chondrosarcoma, H1 2016 7
Number of Products under Development for Chondrosarcoma - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Top 10 Targets, H1 2016 23
Number of Products by Stage and Top 10 Targets, H1 2016 23
Number of Products by Top 10 Mechanism of Actions, H1 2016 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 25
Number of Products by Routes of Administration, H1 2016 27
Number of Products by Stage and Routes of Administration, H1 2016 27
Number of Products by Molecule Types, H1 2016 29
Number of Products by Stage and Molecule Types, H1 2016 29
